
Terry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: November 9th 2018 | Updated: